Vericel Corporation (VCEL)
POSITIVEFundamental
70
Preço
$42.99
Capitalização de Mercado
$2.20B
Parte 1 · Quanto vale a empresa
Visão Geral
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. Vericel Corporation was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014. The company was incorporated in 1989 and is headquartered in Burlington, Massachusetts.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balanço & Liquidez
Receita
$306M
Últimos 12 meses (até 30/06/2026)
Resultado Líquido
$24M
Últimos 12 meses (até 30/06/2026)
Fluxo de Caixa Livre
$25M
Capital Próprio Total
$355M
Passivo Total
$133M
Rácio de Liquidez
5.04
Cobertura de Juros
28.49
Dívida/EBITDA
4.12
Resultados Por Ação
Receita & Resultado Líquido
Fluxo de Caixa Livre
Decomposição dos Resultados
Demonstração histórica
Margens ao longo do tempo
A dívida ao longo do tempo
Quanto pesa a dívida
Grelha do crescimento
Crescimento — Receitas
Estimativa de Valor Justo
Valor Justo
$44.40
Preço Atual
$42.99
Margem de Segurança
+3.2%
Intervalo de Valor Justo
$30.48 - $58.33
Métodos de Estimativa
Métricas de Avaliação
Rácio P/E
88.13
ROE
4.7%
Rácio P/B
5.85
P/FCF
35.13
Margem Bruta
74.6%
ROIC
3.2%
Radar de Rentabilidade
Value Creation (Economic Moat)
ROIC
3.2%
WACC
9.8%
ROIC − WACC
-6.6 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Critérios de Análise Fundamental
Aprovado (19)
- EPS shows upward trend
- Price CAGR 30.41%
- Gross Margin 74.6%
- Debt/Equity ratio
- Operating Margin 6.0%
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- Low reliance on intangibles
- Revenue Growth 5Y 17.3%
- Analyst Consensus 86% Buy
- Earnings Surprise avg 484.8%
- Earnings Quality (OCF/NI) 2.88
- Share Dilution -0.4%
- Net Margin Trend 7.9% vs 2.9%
- Piotroski F-Score 9/9
Reprovado (7)
- ROIC 3.2%
- P/FCF 35.13
- P/B Ratio 5.85
- Price below Graham Number
- DCF valuation (Overvalued)
- ROE 6.9%
- PEG Ratio 2.40
Indisponível (1)
- Dividend Payout NaN%
Piotroski F-Score
Saúde financeira sólida
Qualidade dos Resultados
Alta qualidade: resultados respaldados por caixa
Diluição de Ações
A recomprar ações. Favorável ao acionista
Governação
Equipa Executiva
| Nome | Cargo | Idade |
|---|---|---|
| Mr. Dominick C. Colangelo Esq. | CEO, President & Director | 61 |
| Mr. Joseph Anthony Mara Jr. | CFO & Treasurer | 49 |
| Mr. Michael Halpin | Chief Operating Officer | 63 |
| Mr. Sean C. Flynn | Chief Legal Officer | 51 |
| Dr. Jonathan M. Hopper FRCSEd., M.B. Ch.B. | Chief Medical Officer | 63 |
| Mr. Jonathan D. Siegal | Principal Accounting Officer, VP & Corporate Controller | - |
| Mr. Eric Burns | Vice President of Finance & Investor Relations | - |
| Mr. Roland DeAngelis | Chief Marketing Officer | - |
| Mr. Patrick J. Fowler | Senior Vice President of Corporate Development & Strategy | - |
| Mr. Mike Gilligan | Senior Vice President of Sales | - |
Risco de Auditoria
4
Risco do Conselho
3
Risco de Remuneração
6
Risco dos Direitos dos Acionistas
4
Parte 2 · O preço e o momento de entrar
Esta parte não serve para saber se a empresa vale: serve para escolher quando comprá-la, depois que os fundamentos te convenceram. Dentro: análise técnica, potencial, quedas históricas, exposição gama.
Latest News
Recent headlines for VCEL, sourced from Markets Gazette.
- 2/26/2026NEUTRALVericel (VCEL) Q4 2025 Earnings Call Transcript
Biotechnology firm Vericel (VCEL) held its fourth-quarter 2025 earnings conference call. While specific details from the transcript are not yet available, this event is crucial for investors monitoring the company's financial performance and future outlook. Earnings calls are key moments to assess operational health, revenues, profit margins, and management's guidance. The immediate lack of information prevents an in-depth analysis, but the market will keenly await the data release to understand the impact on key products like MACI and Epicel. Investors should remain vigilant for subsequent communications that could influence the stock's valuation.
via Markets Gazette